Skip to main content
RLAY
NASDAQ Life Sciences

Relay Therapeutics Upsizes ATM Program to $463M, Adding $213M in New Capacity

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.3
Mkt Cap
$4.304B
52W Low
$3.025
52W High
$20.79
52W Position info
538% above low
Off High info
7.2% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

RLAY has more than doubled off its 52-week low of $3.025.

Summary

Relay Therapeutics upsized its ATM program by $213 million to a total of $463 million, providing additional financial flexibility following positive clinical data and a strong cash position.


Key Events · Financing and Capital Events · RLAY

  • ATM Program Upsized by $213M

    Amendment No. 1 to the Sales Agreement with TD Cowen adds $212,978,049 in new capacity, bringing the total ATM program to $463 million. Through August 3, 2026, 16,006,569 shares had been sold under the original program, leaving $87 million before the amendment.

  • Financial Impact

    At the assumed offering price of $18.83 per share (July 31, 2026 close), the new capacity represents approximately 11.3 million additional shares, or about 5.2% of outstanding shares. The company's net tangible book value per share would increase from $3.89 to $4.61, but new investors would experience immediate dilution of $14.22 per share.

  • Use of Proceeds

    Proceeds will fund research and clinical development of current or additional pipeline candidates, working capital, and general corporate purposes. The company reported $911 million in cash as of the same-day 8-K, extending runway into 2029.

  • Sales Agent and Commission

    TD Cowen will serve as sales agent, receiving a commission of up to 3.0% of gross proceeds. Sales will be made at market prices on Nasdaq under the ticker RLAY.


Analysis · RLAY · Life Sciences

Relay Therapeutics amended its at-the-market (ATM) sales agreement with TD Cowen, adding $213 million in new capacity to the existing program. The company had already sold $126 million of the original $300 million program, leaving $87 million before this amendment. The upsizing brings the total ATM capacity to $463 million. While ATM programs are dilutive by nature, the company's strong cash position ($911 million as of the same-day 8-K) and recent positive clinical data for zovegalisib suggest this is opportunistic capital raising rather than distress financing. The 3% commission to TD Cowen is standard for such programs.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RLAY was trading at $19.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $3.03 to $20.79. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RLAY - Latest Insights

RLAY
Nov 04, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $17.87 info
Change: -$0.150 (-0.83%) info
Market Cap: $3.997B info
RLAY
Nov 04, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $17.87 info
Change: -$0.150 (-0.83%) info
Market Cap: $3.997B info
RLAY
Sep 22, 2026, 11:23 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $18.54
Real-time Price: $17.87 info
Change: -$0.670 (-4%) info
Market Cap: $3.997B info
RLAY
Aug 25, 2026, 7:43 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $19.88
Real-time Price: $17.87 info
Change: -$2.01 (-10%) info
Market Cap: $3.997B info
RLAY
Aug 06, 2026, 4:40 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $19.04
Real-time Price: $17.87 info
Change: -$1.17 (-6%) info
Market Cap: $3.997B info